The Future of McDonald’s and Merck Revealed on CNBC’s ‘Final Trades’
Merck Faces FDA Setback During CNBC’s “Halftime Report Final Trades,” Joseph Terranova of Virtus Investment Partners discussed Merck & Co., Inc. (MRK) as his final trade. However, Merck recently faced a setback as the FDA issued a Complete Response Letter (CRL) for gefapixant’s New Drug Application. The FDA concluded that the application did not meet ...












